To evaluate the safety and efficacy of Endotone polyherbal capsule in treatment of Endometriosis.
- Conditions
- Health Condition 1: N809- Endometriosis, unspecified
- Registration Number
- CTRI/2022/10/046666
- Lead Sponsor
- Charak Pharma Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1) Female 18 to 45 years of age (inclusive) at the time of screening.
2) Women experiencing endometriosis symptoms like pelvic pain, dysmenorrhea,
Dyspareunia
3) Women with documented diagnosis of endometriosis by either of the following -
a) Laparoscopy or laparotomy
b) VAS test score of 1-7 for dysmenorrhea/dyspareunia and/or Pelvic pain due to
endometriosis.
c) Clinical features, pelvic examination findings
d) Diagnosed case of endometriosis by any radio-imaging techniques.
4) Recurrent Endometriosis after surgery
1) Participant having chronic pelvic pain that is not caused by endometriosis
2) Patients with concomitant hormonal treatment, including oral contraceptive pills.
3)Patients with known systemic diseases (e.g., hypertension, diabetes, coronary, renal, and
hepatic diseases).
4) Patients with known malignancy.
5) Menopausal women, Pregnancy, Lactating women.
6) Large chocolate cysts
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain reduction in endometriosisTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method Improved quality of life.Timepoint: 6 Months